Cara Therapeutics (CARA) : Zacks Investment Research ranks Cara Therapeutics (CARA) as 4, which is a Sell recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. The average broker rating of 4 research analysts is 1, which indicates as a Strong Buy.
Cara Therapeutics (CARA) : The highest short term price target forecast on Cara Therapeutics (CARA) is $24 and the lowest target price is $16. A total of 4 equity analysts are currently covering the company. The average price of all the analysts is $20.5 with a standard deviation of $4.12.
Also, Stifel Nicolaus maintains their rating on the shares of Cara Therapeutics (NASDAQ:CARA). The current rating of the shares is Buy. Equity Analysts at the Firm lowers the price target to $24 per share from $25 per share. The rating by the firm was issued on August 5, 2016.
Cara Therapeutics (NASDAQ:CARA): After opening at $6.13, the stock dipped to an intraday low of $6 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $6.25 and the buying power remained strong till the end. The stock closed at $6.23 for the day, a gain of 2.30% for the day session. The total traded volume was 644,223. The stocks close on the previous trading day was $6.09.
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the bodys peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. CR845 is a peripherally-acting kappa opioid receptor agonist for the treatment of both acute and chronic pain. I.V. CR845 is an injectable version of its peripheral kappa opioid receptor agonist, which is designed to provide pain relief without stimulating mu opioid receptors. CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with these cannabinoid receptor subtypes, with no off-target activities.